Literature DB >> 23261218

The effect of the acid-sensitivity of 4-(N)-stearoyl gemcitabine-loaded micelles on drug resistance caused by RRM1 overexpression.

Saijie Zhu1, Piyanuch Wonganan, Dharmika S P Lansakara-P, Hannah L O'Mary, Yue Li, Zhengrong Cui.   

Abstract

Chemoresistance is a major issue for most gemcitabine-related chemotherapies. The overexpression of ribonucleotide reductase subunit M1 (RRM1) plays a key role in gemcitabine resistance. In this study, we synthesized a new highly acid-sensitive amphiphilic micelle material by conjugating hydrophilic polyethylene glycol with a hydrophobic stearic acid derivative (C18) using a hydrazone bond, which was named as PHC-2. A lipophilic prodrug of gemcitabine, 4-(N)-stearoyl gemcitabine (GemC18), was loaded into micelles prepared with PHC-2, a previously synthesized less acid-sensitive PHC-1, and their acid-insensitive counterpart, PAC. GemC18 loaded in acid-sensitive micelles can overcome gemcitabine resistance, and GemC18 in the highly acid-sensitive PHC-2 micelles was more cytotoxic than in the less acid-sensitive PHC-1 micelles. Mechanistic studies revealed that upon cellular uptake and lysosomal delivery, GemC18 in the acid-sensitive micelles was released and hydrolyzed more efficiently. Furthermore, GemC18 loaded in the highly acid-sensitive PHC-2 micelles inhibited the expression of RRM1 and increased the level of gemcitabine triphosphate (dFdCTP) in gemcitabine resistant tumor cells. The strategy of delivering lipophilized nucleoside analogs using highly acid-sensitive micelles may represent a new platform technology to increase the antitumor activity of nucleoside analogs and to overcome tumor cell resistance to them.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23261218      PMCID: PMC3552003          DOI: 10.1016/j.biomaterials.2012.11.053

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  43 in total

1.  Synthesis and preliminary antitumor activity evaluation of a DHA and doxorubicin conjugate.

Authors:  Yuqiang Wang; Lianfa Li; Wei Jiang; Zhaoqi Yang; Zaijun Zhang
Journal:  Bioorg Med Chem Lett       Date:  2006-03-24       Impact factor: 2.823

Review 2.  Chemoresistance in non-small cell lung cancer.

Authors:  Pascal Sève; Charles Dumontet
Journal:  Curr Med Chem Anticancer Agents       Date:  2005-01

3.  Lysosomal delivery of a lipophilic gemcitabine prodrug using novel acid-sensitive micelles improved its antitumor activity.

Authors:  Saijie Zhu; Dharmika S P Lansakara-P; Xinran Li; Zhengrong Cui
Journal:  Bioconjug Chem       Date:  2012-04-18       Impact factor: 4.774

Review 4.  Gemcitabine: a pharmacologic and clinical overview.

Authors:  M Barton-Burke
Journal:  Cancer Nurs       Date:  1999-04       Impact factor: 2.592

Review 5.  Preclinical characteristics of gemcitabine.

Authors:  W Plunkett; P Huang; V Gandhi
Journal:  Anticancer Drugs       Date:  1995-12       Impact factor: 2.248

6.  Simultaneous determination of deoxyribonucleoside in the presence of ribonucleoside triphosphates in human carcinoma cells by high-performance liquid chromatography.

Authors:  L A Decosterd; E Cottin; X Chen; F Lejeune; R O Mirimanoff; J Biollaz; P A Coucke
Journal:  Anal Biochem       Date:  1999-05-15       Impact factor: 3.365

7.  Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs.

Authors:  Maria Laura Immordino; Paola Brusa; Flavio Rocco; Silvia Arpicco; Maurizio Ceruti; Luigi Cattel
Journal:  J Control Release       Date:  2004-12-10       Impact factor: 9.776

8.  Overexpression of ribonucleotide reductase as a mechanism of resistance to 2,2-difluorodeoxycytidine in the human KB cancer cell line.

Authors:  Y G Goan; B Zhou; E Hu; S Mi; Y Yen
Journal:  Cancer Res       Date:  1999-09-01       Impact factor: 12.701

9.  Intracellular delivery of doxorubicin with RGD-modified sterically stabilized liposomes for an improved antitumor efficacy: in vitro and in vivo.

Authors:  Xiao-Bing Xiong; Yue Huang; Wan-Liang Lu; Xuan Zhang; Hua Zhang; Tsuneji Nagai; Qiang Zhang
Journal:  J Pharm Sci       Date:  2005-08       Impact factor: 3.534

10.  In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant.

Authors:  Andries M Bergman; Paul P Eijk; Veronique W T Ruiz van Haperen; Kees Smid; Gijsbert Veerman; Isabelle Hubeek; Paul van den Ijssel; Bauke Ylstra; Godefridus J Peters
Journal:  Cancer Res       Date:  2005-10-15       Impact factor: 12.701

View more
  20 in total

Review 1.  Lipid-Drug Conjugate for Enhancing Drug Delivery.

Authors:  Danielle Irby; Chengan Du; Feng Li
Journal:  Mol Pharm       Date:  2017-01-24       Impact factor: 4.939

2.  Lipid nanoparticles with minimum burst release of TNF-α siRNA show strong activity against rheumatoid arthritis unresponsive to methotrexate.

Authors:  Abdulaziz M Aldayel; Hannah L O'Mary; Solange A Valdes; Xu Li; Sachin G Thakkar; Bahar E Mustafa; Zhengrong Cui
Journal:  J Control Release       Date:  2018-05-31       Impact factor: 9.776

Review 3.  Applications of RNA interference in the treatment of arthritis.

Authors:  Muhammad Farooq Rai; Hua Pan; Huimin Yan; Linda J Sandell; Christine T N Pham; Samuel A Wickline
Journal:  Transl Res       Date:  2019-07-10       Impact factor: 7.012

4.  Multifunctional polymersomes for cytosolic delivery of gemcitabine and doxorubicin to cancer cells.

Authors:  Rahul Nahire; Manas K Haldar; Shirshendu Paul; Avinash H Ambre; Varsha Meghnani; Buddhadev Layek; Kalpana S Katti; Kara N Gange; Jagdish Singh; Kausik Sarkar; Sanku Mallik
Journal:  Biomaterials       Date:  2014-05-05       Impact factor: 12.479

5.  Targeting of tumor-associated macrophages made possible by PEG-sheddable, mannose-modified nanoparticles.

Authors:  Saijie Zhu; Mengmeng Niu; Hannah O'Mary; Zhengrong Cui
Journal:  Mol Pharm       Date:  2013-08-06       Impact factor: 4.939

6.  Phase-Separated Liposomes Enhance the Efficiency of Macromolecular Delivery to the Cellular Cytoplasm.

Authors:  Zachary I Imam; Laura E Kenyon; Grant Ashby; Fatema Nagib; Morgan Mendicino; Chi Zhao; Avinash K Gadok; Jeanne C Stachowiak
Journal:  Cell Mol Bioeng       Date:  2017-05-22       Impact factor: 2.321

7.  Just getting into cells is not enough: mechanisms underlying 4-(N)-stearoyl gemcitabine solid lipid nanoparticle's ability to overcome gemcitabine resistance caused by RRM1 overexpression.

Authors:  Piyanuch Wonganan; Dharmika S P Lansakara-P; Saijie Zhu; Melisande Holzer; Michael A Sandoval; Mangalika Warthaka; Zhengrong Cui
Journal:  J Control Release       Date:  2013-04-06       Impact factor: 9.776

8.  Tumor-Associated Macrophage-Mediated Targeted Therapy of Triple-Negative Breast Cancer.

Authors:  Mengmeng Niu; Solange Valdes; Youssef W Naguib; Stephen D Hursting; Zhengrong Cui
Journal:  Mol Pharm       Date:  2016-04-26       Impact factor: 4.939

9.  PD-1 siRNA-Encapsulated Solid Lipid Nanoparticles Downregulate PD-1 Expression by Macrophages and Inhibit Tumor Growth : PD-1 siRNA-Encapsulated Solid Lipid Nanoparticles.

Authors:  Mahmoud S Hanafy; Stephanie Hufnagel; Andrea N Trementozzi; Wedad Sakran; Jeanne C Stachowiak; John J Koleng; Zhengrong Cui
Journal:  AAPS PharmSciTech       Date:  2021-01-31       Impact factor: 3.246

10.  Light-Responsive Micelles Loaded With Doxorubicin for Osteosarcoma Suppression.

Authors:  Jiayi Chen; Chenhong Qian; Peng Ren; Han Yu; Xiangjia Kong; Chenglong Huang; Huanhuan Luo; Gang Chen
Journal:  Front Pharmacol       Date:  2021-06-18       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.